Eli Lilly and Company (NYSE:LLY) Trading Up 1.5% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 1.5% during mid-day trading on Friday . The stock traded as high as $800.17 and last traded at $799.89. 814,889 shares were traded during trading, a decline of 75% from the average session volume of 3,206,517 shares. The stock had previously closed at $788.19.

Analysts Set New Price Targets

Several research firms recently commented on LLY. Bank of America dropped their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Berenberg Bank boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Guggenheim increased their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Finally, Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Trading Up 0.9 %

The stock’s 50 day simple moving average is $851.90 and its 200 day simple moving average is $870.26. The firm has a market cap of $755.04 billion, a PE ratio of 85.98, a PEG ratio of 2.99 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Massmutual Trust Co. FSB ADV boosted its position in Eli Lilly and Company by 9.8% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 3,534 shares of the company’s stock valued at $3,200,000 after buying an additional 315 shares during the period. Beese Fulmer Investment Management Inc. grew its stake in shares of Eli Lilly and Company by 3.4% in the second quarter. Beese Fulmer Investment Management Inc. now owns 604 shares of the company’s stock worth $547,000 after purchasing an additional 20 shares during the last quarter. HBW Advisory Services LLC increased its holdings in Eli Lilly and Company by 40.6% during the 2nd quarter. HBW Advisory Services LLC now owns 917 shares of the company’s stock valued at $830,000 after purchasing an additional 265 shares during the period. ST Germain D J Co. Inc. raised its position in Eli Lilly and Company by 109.4% during the 2nd quarter. ST Germain D J Co. Inc. now owns 2,693 shares of the company’s stock valued at $2,438,000 after purchasing an additional 1,407 shares during the last quarter. Finally, Bank & Trust Co purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $11,133,000. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.